Vitritis secondary to acute toxoplasma chorioretinitis MedDRA version: 8.1 Level: LLT Classification code 10008770 Term: Chorioretinitis due to toxoplasmosis
Conditions
Interventions
Trade Name: Dalacin C Phosphate
Product Name: Clindamycin
Pharmaceutical Form: Concentrate for solution for injection
INN or Proposed INN: CLINDAMYCIN P
Sponsors
Moorfields Eye Hospital NHS Foundation Trust
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. primary or secondary toxoplasma chorioretinitis (TCR) with no macular involvement 2. vitritis reducing vision to 6/12 or less Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: 1. primary or secondary TCR with macular retinitis or lesion within 1 Disc area of disc 2. known steroid responder 3. systemic treatment for TCR already commenced 4. risk of HIV or other immunosuppression from history
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: The aim of this study is to investigate the use of intravitreal clindamycin and dexamethasone in avoidance of the use of systemic antibiotics and systemic steroids in treatment of patients with severe vitritis secondary to toxoplasma chorioretinitis (TCR).;Secondary Objective: ;Primary end point(s): • Quiescence – defined as clinical resolution of TCR. | — |
Countries
United Kingdom
Outcome results
None listed